Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA.
Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
Interv Neuroradiol. 2024 Apr;30(2):175-182. doi: 10.1177/15910199221127070. Epub 2022 Sep 13.
While it is thought that Borden Type I intracranial dural arteriovenous fistula (dAVF) have a benign clinical course, their management remains controversial.
A comparative meta-analysis was completed to evaluate the outcomes of intervention verses observation of Borden Type I intracranial dAVF. Outcome measures included: grade progression, worsening symptoms, death due to dAVF, permanent complications other than death, functional independence (mRS 0-2), and rate of death combined with permanent complication, were evaluated. Risk differences (RD) were determined using a random effects model.
Three comparative studies combined with the authors' institutional experience resulted in a total of 469 patients, with 279 patients who underwent intervention and 190 who were observed. There was no significant difference in dAVF grade progression between the intervention and observation arms, 1.8% vs. 0.7%, respectively (RD: 0.01, 95% CI: -0.02 to 0.04, = 0.49), or in symptom progression occurring in 31/279 (11.1%) intervention patients and 11/190 (5.8%) observation patients (RD: 0.03, CI: -0.02 to 0.09, = 0.28). There was also no significant difference in functional independence on follow up. However, there was a significantly higher risk of dAVF related death, permanent complication from either intervention or dAVF related ICH or stroke in the intervention group (11/279, 3.9%) compared to the observation group (0/190, 0%) (RD: 0.04, CI: 0.1 to 0.06, = 0.007).
Intervention of Borden Type I dAVF results in a higher risk of death or permanent complication, which should be strongly considered when deciding on management of these lesions.
虽然人们认为博登 I 型颅内硬脑膜动静脉瘘(dAVF)具有良性的临床病程,但它们的治疗仍然存在争议。
进行了一项比较性荟萃分析,以评估博登 I 型颅内 dAVF 的干预与观察治疗的结果。结果测量包括:dAVF 分级进展、症状恶化、dAVF 相关死亡、除死亡以外的永久性并发症、功能独立性(mRS 0-2),以及死亡和永久性并发症的综合发生率。采用随机效应模型确定风险差异(RD)。
三项比较性研究结合作者所在机构的经验,共纳入 469 例患者,其中 279 例患者接受了干预,190 例患者接受了观察。干预组和观察组 dAVF 分级进展的差异无统计学意义,分别为 1.8%和 0.7%(RD:0.01,95%CI:-0.02 至 0.04, = 0.49),或在 279 例干预患者中有 31 例(11.1%)和 190 例观察患者中有 11 例(5.8%)出现症状进展(RD:0.03,CI:-0.02 至 0.09, = 0.28)。随访时的功能独立性也没有显著差异。然而,干预组的 dAVF 相关死亡率和永久性并发症的风险显著高于观察组(11/279,3.9%),而观察组无患者死亡或发生永久性并发症(0/190,0%)(RD:0.04,CI:0.1 至 0.06, = 0.007)。
博登 I 型 dAVF 的干预会增加死亡或永久性并发症的风险,在决定这些病变的治疗方案时应充分考虑这一点。